Rosen Law Firm Urges BioAge Labs Investors to Seek Counsel Before Deadline

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) --

Overview: The Rosen Law Firm, a globally recognized law firm dedicated to investor rights, is reminding individuals who purchased stock in BioAge Labs, Inc. (NASDAQ: BIOA) in relation to its registration statement for the initial public offering (IPO) on September 26, 2024, about an important deadline. Investors should be aware that the deadline to become a lead plaintiff in a related class action lawsuit is on March 10, 2025.

Investor Compensation: If you acquired shares of BioAge Labs during this period, you may be eligible for compensation without having to pay any out-of-pocket costs, thanks to a contingency fee setup offered by the Rosen Law Firm.

Next Steps: To participate in the BioAge class action, investors can visit this link or contact Phillip Kim, Esq. at 866-767-3653 for more information. A class action lawsuit has already been initiated. If you wish to be appointed as lead plaintiff, you must file a motion with the court before the March 10, 2025 deadline. Being a lead plaintiff means you will represent the interests of other affected investors in guiding the litigation.

Why Choose Rosen Law Firm: Investors are encouraged to select legal representation that has demonstrated success and experience in leadership roles in class action cases. Some firms sending out notifications do not have the same level of expertise or recognition. Many of these firms simply act as intermediaries and do not litigate securities class actions themselves. Be mindful when choosing your counsel. The Rosen Law Firm has a proven track record, focusing on securities class actions and derivative litigation on behalf of investors around the world. They previously secured the largest securities class action settlement against a Chinese company at that time and were ranked as number one by ISS Securities Class Action Services for the number of settlements achieved in 2017. The firm consistently ranks in the top tier annually, having recovered hundreds of millions of dollars for investors. Notably, in 2019 alone, they obtained over $438 million on behalf of their clients.

Case Details: The lawsuit stems from claims that BioAge Labs made certain representations regarding its lead product candidate, azelaprag, in relation to its ongoing STRIDES clinical trial, with expectations for topline results in 2025. The company also communicated its partnership with Eli Lilly's Chorus clinical development organization, which would assist in the trial's design and execution. Furthermore, defendants discussed the prospects of a second Phase 2 clinical trial combining azelaprag with semaglutide for treating obesity in individuals aged 18 and above. The IPO asserted there were no safety related concerns, indicating the company expected to meet its primary endpoint goals.

However, contrary to these statements, BioAge Labs halted the ongoing STRIDES Phase 2 study after elevated liver enzyme levels were observed in several participants, indicating potential organ damage. Consequently, the defendants terminated the clinical trial and ceased further enrollment. The lawsuit asserts that the prior disclosures failed to adequately inform investors of the risks associated with liver transaminitis present in earlier Phase 1 trials and preclinical toxicology studies. Therefore, the information provided in BioAge’s registration statement was allegedly false and misleading during the IPO process, resulting in investor damages once the truth became public.

To join the BioAge class action, visit this link or call Phillip Kim, Esq. at 866-767-3653 for further details on the class action.

Note: A class has yet to be certified. Until then, individuals are not represented by counsel unless retained. You have the option to select your own counsel or remain an absent class member and take no action for now. Your ability to share in any future recovery does not rely upon being a lead plaintiff.

Stay connected with us for updates on LinkedIn, Twitter, or Facebook.

Disclaimer: Prior results do not guarantee the same outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

BioAge, investors, lawsuit